Dr. Jared D. Acoba
Claim this profileQueen's Medical Center
Studies Cervical Adenocarcinoma
Studies Parotid Gland Cancer
18 reported clinical trials
38 drugs studied
Area of expertise
1Cervical Adenocarcinoma
Stage IV
Stage III
BRAF negative
2Parotid Gland Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Jared D. Acoba is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Jared D. Acoba
Clinical Trial Related2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Jared D. Acoba has experience with
- Fluorouracil
- Oxaliplatin
- Leucovorin Calcium
- Irinotecan Hydrochloride
- Atezolizumab
- Irinotecan
Breakdown of trials Jared D. Acoba has run
Cervical Adenocarcinoma
Parotid Gland Cancer
Colon Cancer
Pancreatic Cancer
Liver Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Jared D. Acoba specialize in?
Is Jared D. Acoba currently recruiting for clinical trials?
Are there any treatments that Jared D. Acoba has studied deeply?
What is the best way to schedule an appointment with Jared D. Acoba?
What is the office address of Jared D. Acoba?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.